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The association of endogenous subclinical hyperthyroidism (SHyper) with cardiovascular mortality is
controversial. This may reflect the different causes of endogenous SHyper in the population studied
due to differences in iodine intake, and different selection criteria, e.g. sex, age, and race, the cutoff for
serum TSH level, the duration of follow-up, and the presence of co-morbidities. A small sample size of
SHyper patients could have caused a low statistical power in some of these studies. In other studies,
the results were not adjusted for relevant confounders. Importantly, various meta-analyses have also
given conflicting results. This issue of the European Journal of Endocrinology contains two articles
that address the association between endogenous SHyper and cardiovascular and total mortality: one
study was conducted in a north-eastern German population and the other in a Japanese–Brazilian
population. After adjusting for relevant confounders, there was no association between decreased
serum TSH levels and all-cause and cardiovascular mortality in the Pomerania study; on the contrary,
all-cause mortality and cardiovascular mortality were significantly higher for individuals with
SHyper in the Japanese–Brazilian population. Interestingly, both studies had similar characteristics in
terms of selection criteria and duration of follow-up. It remains controversial whether or not to treat
middle-aged patients with low serum TSH levels. Large prospective randomized controlled double-
blind studies of young and middle-aged patients with SHyper and without underlying cardiac disease
are required to assess the potential benefits of treating endogenous SHyper in these age groups.
European Journal of Endocrinology 162 587–589Subclinical thyroid dysfunction (STD) has been associ-
ated with important cardiovascular risk factors.
However, it remains controversial whether this disease
is associated with an increased cardiovascular mortality
in middle-aged and older adults (1). Importantly,
various meta-analyses have also given conflicting
results (2). In particular, persistent subclinical
hyperthyroidism (SHyper) has been associated with
repeated subnormal (0.1–0.4 mIU/l) or undetectable
serum thyrotropin (TSH) levels (!0.1 mIU/l) and
normal free thyroid hormone levels (1). It may be
related to exogenous conditions during TSH suppression
induced by L-thyroxine (T4) therapy, or endogenous
conditions due to thyroid autonomy (1). The prevalence
of endogenous SHyper is between 0.7 and 7% or higher,
and it is inversely correlated with the population’s iodine
intake (1). Its prevalence is also related to the degree of
TSH suppression, with the age of the population studied
being higher in subjects above the age of 60–70 years
with low serum TSH levels (1). It is well recognized that
the risk of adverse effects of SHyper is higher in elderly
subjects because this disease could increase the risk ofndocrinologyatrial fibrillation in the presence of subnormal (3) and
undetectable serum TSH levels (3, 4).
Studies on the relationship between cardiovascular
morbidity and mortality in exogenous SHyper (5–8)
induced by long-term treatment with L-T4 have yielded
conflicting results (9). In the very recent large
population-based study by Flynn et al. (6), among
17 684 patients affected by exogenous SHyper (mean
age 61.6 years), those with undetectable serum TSH
levels (%0.03 mU/l) were at increased risk for cardio-
vascular morbidity and mortality, dysrhythmias, and
fractures: hazard ratio (HR) 1.37 (1.17–1.60), 1.6
(1.10–2.33), and 2.02 (1.55–2.62) respectively, after
adjusting for age, sex, history of a thyroid condition,
history of cardiovascular disease, and the presence of
diabetes, during a median follow-up of 4.5 years. In the
same population, patients with subnormal serum TSH
levels did not have an increased risk of any of these
outcomes. This is in line with a previous study in which
low serum TSH levels (%0.5 mU/l) were not signi-
ficantly linked to excess mortality among older women
using thyroid hormone (5). On the contrary, thereDOI: 10.1530/EJE-09-1095
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(!0.3 mU/l) (7) and high free T4 (FT4) values had
adverse prognostic effects in very elderly subjects (7, 8).
Thus far, only a few studies have examined the risk of
cardiovascular mortality in patients with endogenous
SHyper (3, 10, 11); these were performed inmiddle-aged
(11) and elderly subjects (3, 10). Three studies have
been performed in patients with co-morbidity associated
with SHyper (12–14). Similar to exogenous disease,
the association of endogenous SHyper with cardio-
vascular mortality is controversial (2). This may reflect
the different causes of endogenous SHyper in the popu-
lation studied due to differences in iodine intake, and
different selection criteria, e.g. sex, age, and race, the
cutoff for serum TSH level, the duration of follow-up, and
the presence of co-morbidities. A small sample size of
SHyper patients could have caused a low statistical
power in some of these studies. In other studies, the
results were not adjusted for relevant confounders.
A recent meta-analysis concluded that evidence of an
association between heart disease events and mortality
in SHyper was weak (15). However, another recent
meta-analysis concluded that untreated endogenous
SHyper is more harmful in patients with co-morbidities
such as cardiac disease and diabetes mellitus, and in
patients recovering from stroke (16).
This issue of the European Journal of Endocrinology
contains two articles that address the timely issue of the
association between endogenous SHyper and cardio-
vascular and total mortality: one study was conducted
in a north-eastern German population (17) and the
other in a Japanese–Brazilian population (18). In the
former study, Itterman et al. analyzed the data of 3651
individuals (aged 20–79 years) living in Pomerania,
without known thyroid disorder or thyroid treatment,
and found that 270 individuals had decreased serum
TSH levels (7.4%). A total of 299 individuals (6.9%) died
during the follow-up. More individuals with decreased
serum TSH levels (15.98 deaths per 1000 person
years) died than individuals with serum TSH levels
within the reference range (9.45 deaths per 1000
person years; relative risk 1.67; 95% confidence interval
(CI) 1.19, 2.33). The cause of death was not available
for 41 individuals. Survival time was also shorter in
subjects with decreased serum TSH levels than in the
euthyroid individuals (log-rank test; PZ0.003).
However, after adjusting for age and sex, there was no
association between decreased serum TSH levels and
all-cause mortality (HR 0.95; 95% CI 0.67, 1.36).
Furthermore, Cox regression analysis revealed no
significant association between decreased serum TSH
levels and cardiovascular (HR 1.08; 95% CI 0.61, 1.91;
PZ0.846) and cancer mortality (HR 1.05; 95% CI
0.57, 1.93; PZ0.890). The results did not change after
applying a different cutoff for decreased serum TSH
levels, and no association was found for all-cause,
cancer, and cardiovascular mortality in patients with
subclinical and overt hyperthyroidism (17).www.eje-online.orgIn the second prospective observational study, Sgarbi
et al. observed the entire population (nZ1751) living in
Bauru (Sa˜o Paulo, Brazil), agedR30 years, to assess the
relationship between STD with all-cause and cardiovas-
cular mortality during a 7.5-year follow-up (18). A total
of 1330 (76%) individuals agreed to participate
in the study; of these, 69 were affected by SHyper.
Interestingly, at baseline, no association was found
between STD and cardiovascular disease. However, all-
cause mortality was significantly higher for individuals
with SHyper (20.3%) and for those with subclinical
hypothyroidism (SHypo) (13.1%) than for individualswith
euthyroidism (5.7%; P!0.0001). The Kaplan–Meier
analysis revealed higher overall mortality in SHyper
(P!0.0001) and SHypo (PZ0.0035) individuals
than in the euthyroid group. Cardiovascular mortality
was significantly associated with SHyper (P!0.0001);
this finding emerged after 4 years of follow-up. The Cox
regression analysis revealed that these significant associ-
ations persisted even after adjusting for age, sex, and
multiple potential confounders (18).
How can we explain the different results of these
two studies?
Interestingly, both studies had similar characteristics
in terms of selection criteria and duration of follow-up.
In fact, both studies were conducted in areas of previous
iodine deficiency in which iodine supplementation was
implemented in recent years; the prevalence of SHyper
was similar (6.2% in the Japanese–Brazilian study and
7.4% in the West Pomerania study); both studies were
performed on the entire population, including women
and men with a wide age range (mean age 60 years);
the length of the follow-up was similar (7.5 years in the
Japanese–Brazilian study and 8.5 years in the West
Pomerania study); and lastly, both studies excluded
subjects who self-reported thyroid disease or who were
taking thyroid medications (although in the Japanese–
Brazilian cohort, subjects using drugs interfering with
thyroid function were excluded).
SerumTSH, free triiodothyronine (FT3), and FT4 levels
were determined in the north-eastern German popu-
lation study (17). Decreased TSH was defined as serum
TSH levels below 0.25 mIU/l, according to the reference
range recently established for this region (0.25–2.12
mIU/l). In the Japanese–Brazilian study, the TSH cutoff
for SHyper was below 0.45 mU/l with normal FT4
levels; FT3 levels were not determined in this study (18).
There were some limitations in both these studies.
First, only baseline thyroid function test results are
reported, so we do not know whether the disease was
stable, progressive, or reversible after diagnosis.
However, this is a limit shared by many epidemiological
studies of patients with SHyper. Secondly, neither
study provides information about the treatment of
participants after baseline diagnosis.
In the study by Ittermann et al. patients were
informed about their thyroid dysfunction during the
5-year follow-up (17). The knowledge of their thyroid
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doctors to pay more attention to their clinical condition.
Treatment of their thyroid dysfunction or treatment of
cardiac adverse effects related to SHyper may have
influenced the survival rate in this study.
Interestingly, similar to the results reported by Sgarbi
et al. obtained in middle-aged and elderly individuals
(18), an increased circulatory mortality in patients with
mild SHyper was observed by Parle et al. (10) during the
first 5 years of follow-up in elderly subjects with mild
SHyper. On the contrary, Parle et al. did not find an
association between SHyper and either all-cause or
circulatory mortality over a complete follow-up period
of 10 years; the authors attributed these results to the
fact that many patients died before the census date (10).
In their studies, Sgarbi et al. (18) and Itterman et al.
(17) focused on mortality and did not evaluate the
risk of atrial fibrillation, cerebrovascular disease, or
fracture, which are well-recognized consequences of
SHyper (1, 2). In fact, in the West Pomerania study,
participants with decreased serum TSH levels more
frequently reported a history of stroke, were more often
hypertensive, and had higher fibrinogen levels than
euthyroid subjects (17). These data support the
argument in favor of treating elderly patients with
SHyper rather than simply monitoring them, although
there are no data showing the benefit of treating elderly
patients affected by SHyper. Treatment is safe and less
expensive than some serious potential complications
related to SHyper in elderly subjects.
It remains controversial whether or not to treat
middle-aged patients with low serum TSH levels (2).
Large prospective randomized controlled double-blind
studies of young and middle-aged patients with SHyper
and without important cardiovascular risk factors and
underlying cardiac disease are required to assess the
potential benefits of treating endogenous SHyper in
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